India, June 24 -- Biocon Biologics Limited, a global, fully integrated biosimilars company, has announced a strategic partnership with the National Cancer Society of Malaysia (NCSM) to roll out a Patient Assistance Program (PAP) aimed at improving access to affordable and high-quality biosimilars for underserved cancer patients across Malaysia.
Under this collaboration, Biocon Biologics will supply quality-assured oncology biosimilars—including Trastuzumab, Pegfilgrastim, and Bevacizumab—from its product portfolio. NCSM will oversee patient enrollment and manage the distribution of medications through its established healthcare services network. The initiative combines Biocon's scientific and manufacturing capabilities with NCS...